Education
About Us
Working with TipRanks
Follow Us
Disc Medicine, Inc. (IRON)
:IRON
IRON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$30.82 - $68.73
Previous CloseN/A
Volume41.94K
Average Volume (3M)386.77K
Market Cap
$2.11B
Enterprise Value$1.86B
Total Cash (Recent Filing)$694.66M
Total Debt (Recent Filing)$30.64M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Aug 08, 2025EPS Estimate
-1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding34,634,296
10 Day Avg. Volume400,635
30 Day Avg. Volume386,769
Financial Highlights & Ratios
PEG Ratio-9.23
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio-19.04
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.88K
Enterprise Value/Ebitda-4.09
Forecast
1Y Price Target
$93.63Price Target Upside54.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Disc Medicine News
PremiumCompany Announcements
Disc Medicine Elects Nadim Ahmed as DirectorBulls Say, Bears Say
Bulls Say
Commercial PotentialIRON's streamlined regulatory path in EPP is expected to substantially accelerate time to commercialization while unlocking meaningful value for IRON shares.
Regulatory ApprovalIRON announced positive feedback from the FDA following a pre-NDA meeting for lead asset bitopertin in erythropoietic protoporphyria.
Safety And EfficacyManagement emphasized the remarkable safety profile of bitopertin, with only mild adverse effects reported after 2+ years of exposure.
Bears Say
Competitive And Financial ChallengesRisks to the stock rating and price target include safety, clinical, regulatory, competition, and financing challenges inherent to all development.
Development RisksDisc Medicine's DISC-0974 is still under evaluation for safety and efficacy, which poses inherent risks in its development for myelofibrosis patients with anemia.
Regulatory RisksSome risk will continue to be priced in for bitopertin, as full approval and marketing authorization outside the US depend on the ongoing confirmatory trial's positive outcome.
Options Prices
Currently, No data available
---
Ownership Overview
16.33% Insiders
24.08% Mutual Funds
0.07% Other Institutional Investors
50.39% Public Companies and
Individual Investors
IRON FAQ
What was Disc Medicine, Inc.’s price range in the past 12 months?
Disc Medicine, Inc. lowest stock price was $30.82 and its highest was $68.73 in the past 12 months.
What is Disc Medicine, Inc.’s market cap?
Disc Medicine, Inc.’s market cap is $2.11B.
When is Disc Medicine, Inc.’s upcoming earnings report date?
Disc Medicine, Inc.’s upcoming earnings report date is Aug 08, 2025 which is in 13 days.
How were Disc Medicine, Inc.’s earnings last quarter?
Disc Medicine, Inc. released its earnings results on May 07, 2025. The company reported -$1.02 earnings per share for the quarter, beating the consensus estimate of -$1.107 by $0.087.
Is Disc Medicine, Inc. overvalued?
According to Wall Street analysts Disc Medicine, Inc.’s price is currently Undervalued.
Does Disc Medicine, Inc. pay dividends?
Disc Medicine, Inc. does not currently pay dividends.
What is Disc Medicine, Inc.’s EPS estimate?
Disc Medicine, Inc.’s EPS estimate is -1.13.
How many shares outstanding does Disc Medicine, Inc. have?
Disc Medicine, Inc. has 34,634,296 shares outstanding.
What happened to Disc Medicine, Inc.’s price movement after its last earnings report?
Disc Medicine, Inc. reported an EPS of -$1.02 in its last earnings report, beating expectations of -$1.107. Following the earnings report the stock price went up 2.278%.
Which hedge fund is a major shareholder of Disc Medicine, Inc.?
Currently, no hedge funds are holding shares in IRON
Disc Medicine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$93.63 (54.56% Upside)
$93.63 (54.56% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $40.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.95%
12-Months-Change
Fundamentals
Return on Equity
-23.34%
Trailing 12-Months
Asset Growth
100.25%
Trailing 12-Months
Company Description
Disc Medicine, Inc.
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
IRON Stock 12 Month Forecast
Average Price Target
$93.63
▲(54.56%Upside)
Technical Analysis
BioCryst
―
Agios Pharma
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―